October 13, 2018

AVTR: Avantor, Inc. Stock

by Wilton Risenhoover

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M)	16,519.76
Enterprise Value ($M)	21,607.86
Book Value ($M)	5,336.30
Book Value / Share	7.86
Price / Book	3.10
NCAV ($M)	-5,106.00
NCAV / Share	-7.52
Price / NCAV	-3.24

Profitability (mra)
Return on Invested Capital (ROIC)	0.02
Return on Assets (ROA)	0.02
Return on Equity (ROE)	0.05

Liquidity (mrq)
Quick Ratio	1.05
Current Ratio	1.61

Balance Sheet (mrq) ($M)
Current Assets	2,321.10
Assets	12,763.40
Liabilities	7,427.10
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	6,967.20
Operating Income	857.20
Net Income	321.10
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	870.00
Cash from Investing	-143.70
Cash from Financing	-843.70
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
02-16	13G/A	Price T Rowe Associates Inc /md/	2.90	0.00
02-14	13G/A	T. Rowe Price Investment Management, Inc.	7.80	-31.01
02-13	13G/A	Vanguard Group Inc	9.66	5.81
02-13	13G	Dodge & Cox	9.00
02-12	13G/A	BlackRock Inc.	6.80	16.48

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-04-26	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-14	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-10-27	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-07-28	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-05-03	375,796	3,029,205	12.41
2024-05-02	536,798	4,081,961	13.15
2024-05-01	351,929	4,481,798	7.85
2024-04-30	558,716	4,669,619	11.96
2024-04-29	716,863	8,537,751	8.40
(click for more detail)

Similar Companies
A – Agilent Technologies, Inc.	AME – AMETEK, Inc.
BIO – Bio-Rad Laboratories, Inc.	BIO.B – Bio-Rad Laboratories, Inc.

Financial data and stock pages provided by
Fintel.io

Related